679 related articles for article (PubMed ID: 22193532)
1. Association of cerebral emboli with accelerated cognitive deterioration in Alzheimer's disease and vascular dementia.
Purandare N; Burns A; Morris J; Perry EP; Wren J; McCollum C
Am J Psychiatry; 2012 Mar; 169(3):300-8. PubMed ID: 22193532
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia.
Purandare N; Voshaar RC; Morris J; Byrne JE; Wren J; Heller RF; McCollum CN; Burns A
Biol Psychiatry; 2007 Aug; 62(4):339-44. PubMed ID: 17531959
[TBL] [Abstract][Full Text] [Related]
3. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study.
Purandare N; Burns A; Daly KJ; Hardicre J; Morris J; Macfarlane G; McCollum C
BMJ; 2006 May; 332(7550):1119-24. PubMed ID: 16648133
[TBL] [Abstract][Full Text] [Related]
4. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
5. Cerebral emboli in the genesis of dementia.
Purandare N; Burns A
J Neurol Sci; 2009 Aug; 283(1-2):17-20. PubMed ID: 19249797
[TBL] [Abstract][Full Text] [Related]
6. Cerebral emboli and paradoxical embolisation in dementia: a pilot study.
Purandare N; Welsh S; Hutchinson S; Riding G; Burns A; McCollum C
Int J Geriatr Psychiatry; 2005 Jan; 20(1):12-6. PubMed ID: 15578671
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of the functional independence measure for assessment of patients with Alzheimer's disease and vascular dementia.
Tanaka N; Nakatsuka M; Ishii H; Nakayama R; Hosaka R; Meguro K
Psychogeriatrics; 2013 Dec; 13(4):199-205. PubMed ID: 24289460
[TBL] [Abstract][Full Text] [Related]
8. Cerebral emboli and depressive symptoms in dementia.
Purandare N; Voshaar RC; Hardicre J; Byrne J; McCollum C; Burns A
Br J Psychiatry; 2006 Sep; 189():260-3. PubMed ID: 16946362
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].
Monllau A; Pena-Casanova J; Blesa R; Aguilar M; Bohm P; Sol JM; Hernandez G
Neurologia; 2007 Oct; 22(8):493-501. PubMed ID: 17602338
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia.
Fuh JL; Wang SJ; Cummings JL
J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1337-41. PubMed ID: 16170072
[TBL] [Abstract][Full Text] [Related]
12. [Vascular factors and the psychopathological picture in Alzheimer's disease].
Idzan LB; Bidzan M
Psychiatr Pol; 2006; 40(5):823-31. PubMed ID: 17217228
[TBL] [Abstract][Full Text] [Related]
13. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
14. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H; Siemers E; Price K; Han B; Selzler KJ; Henley D; Sundell K; Aisen P; Cummings J; Raskin J; Mohs R;
J Alzheimers Dis; 2015; 47(1):205-14. PubMed ID: 26402769
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
[TBL] [Abstract][Full Text] [Related]
16. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.
Liu-Seifert H; Siemers E; Sundell K; Price K; Han B; Selzler K; Aisen P; Cummings J; Raskin J; Mohs R
J Alzheimers Dis; 2015; 43(3):949-55. PubMed ID: 25125457
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
18. Progression of Alzheimer's disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study.
Hallikainen I; Hänninen T; Fraunberg M; Hongisto K; Välimäki T; Hiltunen A; Karppi P; Sivenius J; Soininen H; Koivisto AM;
Int Psychogeriatr; 2013 Aug; 25(8):1335-44. PubMed ID: 23676340
[TBL] [Abstract][Full Text] [Related]
19. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
Bernick C; Cummings J; Raman R; Sun X; Aisen P
Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
[TBL] [Abstract][Full Text] [Related]
20. The need for a consensus in the use of assessment tools for Alzheimer's disease: the Feasibility Study (assessment tools for dementia in Alzheimer Centres across Europe), a European Alzheimer's Disease Consortium's (EADC) survey.
Paulino Ramirez Diaz S; Gil Gregório P; Manuel Ribera Casado J; Reynish E; Jean Ousset P; Vellas B; Salmon E
Int J Geriatr Psychiatry; 2005 Aug; 20(8):744-8. PubMed ID: 16035121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
